Profil
Erin Campany is currently Chief People Officer at Mirum Pharmaceuticals, Inc. since 2025.
Former positions include Senior Director-Global Human Resources at Acorda Therapeutics, Inc. from 2013 to 2017, Head-Human Resources at Immune Design Corp.
from 2017 to 2019, and Vice President-Human Resources at Rapt Therapeutics, Inc. Education includes undergraduate studies at San Jose State University.
Postes actifs de Erin Campany
| Sociétés | Poste | Début |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Responsable des Ressources Humaines | 01/01/2022 |
Anciens postes connus de Erin Campany
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNE DESIGN CORP | Responsable des Ressources Humaines | 01/07/2019 |
| ACORDA THERAPEUTICS, INC. | Responsable des Ressources Humaines | 01/09/2017 |
| RAPT THERAPEUTICS, INC. | Responsable des Ressources Humaines | - |
Formation de Erin Campany
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
San Jose State University
San Jose State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Rapt Therapeutics, Inc.
Rapt Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes oral small molecule therapies for patients | Health Technology |
Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases | Health Technology |
















